U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07219849) titled 'A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure' on Oct. 17.
Brief Summary: This study aims to evaluate the effectiveness and safety of ALDP001 Nasal Spray in treating seasonal allergic rhinitis, and to identify the optimal dosage and administration frequency for this formulation.
Study Start Date: Oct. 17
Study Type: INTERVENTIONAL
Condition:
Seasonal Allergic Rhinitis (SAR)
Intervention:
DRUG: ALDP001 Nasal Spray
Experimental Arm
DRUG: Placebo Nasal spray
Controlled arm
Recruitment Status: RECRUITING
Sponsor: Alixer Nexgen Thera...